Two new broker notes out last week on this one -

Collins Stewart gives a target valuation for the combined entity of 26 million or 156p per share

Edison Investments embedded valuation is 31m - Indicating a 100% gain in share price from current levels. They suggest that using the current embedded valuation model, the current value of Angles six non-exited ventures is only 5.5m - suggesting Angle to be SIGNIFICANTLY UNDERVALUED

Have a look

AGL
Newspapers Guardian .........

But the day's standout performer was Aim-listed Angle, up 129% to 64.25p after it said a cell separation device from its Parsortix division could be used to isolate and capture very small numbers of cancer cells from blood. It is in discussions about the device with a number of cancer research institutes. Collins Stewart said:

We see this as not just a major validation of the Parsortix technology, but a significant broadening of Angle's commercial opportunity. Parsortix is aiming to seek both FDA approval and European CE mark accreditation by mid 2013. Such approvals would open up multi billion dollar clinical markets including cancer detection and monitoring, in addition to the immediate market available for research purposes. By this point, we would anticipate Parsortix to have attracted commercial interest from majors.

guardian
----------------
Technology firm Angle has announced that Parsortix, its 85% owned portfolio company which specialises in medical diagnostics, has achieved a major milestone by validating that its cell separation device can capture cancer cells added to blood.

Parsortix's patented cell separation device can be used, on a reproducible basis, to isolate and capture very small numbers of cancer cells from whole blood, Angle reports.

The device appears to efficiently capture all of the cancer cells, avoiding the risk of failing to detect cancer cells present in a blood sample.

It allows the identification of cancer cells within the device, without requiring a complicated cell extraction process and does not require the use of expensive and sometimes unreliable antibody affinity capture technology to isolate the cancer cells.

Angle said: "The company has already established discussions with several of the world's leading cancer research institutes and there is strong interest in such a product, which would not require regulatory approval for use for research purposes. The target is to establish sales of the product for research purposes as early as the second half of 2012.

"There is also the potential for a corporate partnership with one or more of the largest global medical diagnostic companies and initial discussions have identified encouraging interest in a commercial collaboration. This will be explored further over the coming months."

The group added: "There are major clinical markets for a simple CTC [circulating tumour cells] counting product estimated to exceed $4 bn per annum in the United States market alone. The target is to seek FDA [Food and Drug Administration] approval and European CE Mark by mid 2013 enabling sales of product for clinical use."

The CE mark is a mandatory conformity mark for products marketed in the European Union.

livecharts - Angle-announces-new-cancer-detection-device-
--------------
The junior AIM market provided the major fireworks with shares of technology firm Angle soaring to an all-time high of 66p before closing 36.25p or 129 per cent higher at 64.25p. Buyers piled in on hearing that Parsortix, its 85 per cent owned portfolio company which specialises in medical diagnostics, has achieved a major milestone by validating that its cell separation device can capture cancer cells added to blood.

Angle has already had discussions with several of the world cancer research institutes and there is also the potential for a corporate partnership with one or more of the largest global medical diagnostic companies.

Read more: this is money - MARKET-REPORT

Good call gibby

re - dreamcatcher - 29 Sep 2011 11:44 - 88 of 88
Good call gibby


I wonder if you follow the stock, sell at 56p and missed of the way to 79p

re - gibby - 28 Sep 2011 21:02 - 82 of 88
hi macho ref 77 / 81 - you will note i only said consider selling to buy back later, which means keep an eye on level 2 - be sensible as opposed to greedy and if happy cash in - i did not say sell but only consider


that is not what you said, just read it again and stop to cover you bad sugestion.
Any stock with a large rise and large volume will have another day of rise if is two before profit taking is recomended. On small stocks is very difficult to sell and buy back on the same day as MMs use tricks and large spreads, many try it yesterday and had to pay higher price.

gibby - 28 Sep 2011 12:51 - 75 of 91
re - those in before today's hike should consider selling and buying back later!!! :-))))

Machoman its a very good stock. Wish I did have it. gl

lol macho - i said consider sell to buy back not sell read it again - you twisted my words a tad there :-))

however today's low was 51p - high 70 odd pence - i think that speaks for itself - btw

you wont have any problem buying if quick enough

this for me now is one for the future more 2013 before seeing real increases to 3 figures here

pharma is not a cheap industry more funds will be needed and notoriously slow

momentum from p.i.s is all thats left for now here until further news imo

anyhow people could have top sliced remember

hi dc - seen similar to agl many time - even in recent times such as pym / phytopharm, pyc, sar etc - it will happen again

nothing wrong with agl but needs a reality check

hope you are having a good day

gibby

There is no LOL but BAD recomendation from you, you can twisted and turn it 1 million
times. ( if you do not sell how are you going to buy back )

The proof is on the pudding
at the time of saying it was 56p and went this morning to 79p.

re - however today's low was 51p

Your nonsence goes further as you do not know lows and highs of the day also
Missed this morning 23p ( 79 - 56p ) I gain 23p
retracement to 52p this morning you gain 4p ( if you say is time to buy back low of the day)

Just tell me who is right?

Here we go again :-)

well i did say consider - no more

i didnt say - this is a strong sell get out now and buy later - i said consider it is that simple

and i still say it as you may also want to consider buying now to sell later - lol!! then again you might not

I hope someone is not ......... Full as a tick

or maybe ....................Fur coat and no knickers

after all maybe ............The game/the cake is not worth the candle

some need .............. Get one's act together

allways trying to ........ Get a second bite/ two bites at the cherry

too many .....................Shilly-shally

it allways could be ...............Silver lining

macho i hope you made some money here but personally would not want to be hanging around here - this is as i repeat one for the future and next good news rns - iis will purchase once the sp has dropped again - should hit sub 40 in the coming months with ease - no disrespect to the company just the way it is - todays volume was relatively low compared to yesterdays highs - best not to look at the sp - volumes far more important - that is a fact and gl

The marked down at the start, has encourage buyers and is bouncing back fast

54.50p was the lowest price paid on the bounce back.

Moneyam trades gives 81k buys for 48K sells, and yet is down so far.

The buyers are having a good fun to the MMs games and the last one was a large one 25K @ 62p ( 5 times NMS )



moneyam, as usual nothing goes right so chart from others

64.75p +5p

Merchant Securities Initiation Note on ANGLE - 119p price target

Parsortix delivery on capturing CTCs

ANGLE has been making substantial progress since its last fundraising
and, in our view, is poised to deliver on a number of fronts.
Recent demand for the Geomerics Enlighten platform is picking
up, with an exciting picture building in Parsortix, in particular. We
look forward to news flow in the coming months and initiate
coverage on the stock with a BUY rating and 119p price target.

The validation work successfully conducted by Parsortix has demonstrated that
the device it is developing can be used (reproducibly) to isolate and capture small
numbers of cancer cells from whole blood. The device has apparently captured all
of the cancer cells present in blood used in the experiments. We believe that this
achievement and milestone will enable the characterisation of cancer cells within
the device, without the need to extract them or use of the complex assay based
approach of the main competitor technology.

This potential breakthrough could open up a large market opportunity for Parsortix
with opportunities for early revenues through the launch of a research use device.

# We believe that the Parsortix technology has strong value as an applied research
tool, which could be followed by a number of different clinical applications.

#The risks to our investment thesis relate to the failure of one or more technologies
in the various venture businesses and a decline in the revenues derived from the
management-consulting business.

# We initiate coverage of ANGLE with a BUY rating and a target price of 119p,
driven by a sum-of-the-parts valuation of the constituent components of the
business.

had a quick day trade myself here earlier today - easy cash - hope others did also - but i do not intend hanging around despite broker note - this afternoon will be very telling after around 3pm - gla - good luck if anyone stays the course beyond today

Incredible share(not a holder) but will watch.

lol in for another day trade i must be bonkers - seeking 80p! yeeeehaaaaa!!! then out 75p will do!!!

interesting

Resistance 2 103.2
Resistance 1 70.67

relatively low volume shares in circulation